Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience

BACKGROUND: Recent UK clinical guidance advises against continuing trastuzumab (T) beyond disease progression (PD) in the absence of brain metastases in patients with HER-2 positive (+ve) advanced breast cancer .We have retrospectively evaluated the outcome of patients with HER-2+ve locally advanced...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Waddell, T, Kotsori, A, Constantinidou, A, Yousaf, N, Ashley, S, Parton, M, Allen, M, Starling, N, Papadopoulos, P, O'Brien, M, Smith, I, Johnston, S
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2011
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3111155/
https://ncbi.nlm.nih.gov/pubmed/21522147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.138
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars